Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(3):212-216
The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some …